Sequrin launches healthcare claims-integrity prototype

Sequrin Technologies has launched with a working prototype of its investigative intelligence platform and is seeking design partners in South Africa’s medical-schemes sector. The company says the tool is built to help claims-integrity teams investigate suspicious activity with context, while keeping humans in control of fraud decisions.

Why it matters: - South African medical schemes paid R259.3 billion in healthcare benefits in 2024 across about 9.17 million beneficiaries, making claims-integrity work financially important. - Sequrin’s platform is designed to help authorised teams investigate suspicious claims without turning an anomaly into an automatic fraud finding. - The company is positioning the product around investigative context, procedural fairness and clinical judgment.

What happened: - Sequrin Technologies (Pty) Ltd launched with a working prototype of its investigative intelligence platform. - The South African health-tech company is opening discussions with prospective design partners across the medical-schemes industry. - Sequrin is seeking an initial partner from the South African healthcare funding ecosystem. - The company was incorporated in South Africa in August 2026.

The details: - The platform is intended to help authorised claims-integrity teams investigate potentially suspicious healthcare claiming activity. - Sequrin says the system brings together analytical signals, relationships between claims and entities, temporal patterns and relevant case context in a governed investigative workspace. - The product is built around the idea that an unusual claim, provider pattern or statistical anomaly is an investigative signal, not proof of fraud. - The platform is designed to remain human-in-the-loop. - Sequrin surfaces activity for authorised investigation and provides supporting context. - The platform does not independently determine that fraud has occurred, automatically reject claims, sanction healthcare providers or replace existing investigative and governance processes. - Sequrin has built a working browser and desktop prototype. - The company also has a governed synthetic healthcare-claims environment for product development and testing. - Sequrin has not deployed the platform against live medical-scheme claims. - The company is not claiming real-world detection accuracy, financial savings or production performance. - The design-partner programme is open to medical schemes, administrators, managed-care organisations and healthcare claims-integrity teams. - The initial engagement is expected to focus on existing investigative workflows, product assumptions, clinically and operationally meaningful signals, investigator-facing information and evaluation measures. - Any use of real healthcare data would require appropriate information-governance, privacy, security and organisational approvals. - Sequrin ultimately intends to evaluate the platform using measures tied to investigative utility, including relevance of surfaced activity, false-positive burden, time needed to establish case context, investigator effort, explanation completeness and operational reliability. - The company’s broader goal is to support authorised teams examining fraud, waste, abuse and error in healthcare claims. - More information is available in Sequrin’s announcement and on the company’s LinkedIn page.

Between the lines: - Sequrin is avoiding the common trap of presenting fraud detection as a pure machine-learning classification problem. - The company is emphasizing workflow fit, explanation quality and investigator workload over model metrics alone. - Mdingi said the meaningful test is whether the technology remains useful under the realities of claims-integrity work, including false positives, clinical context and operational constraints. - Mdingi also said the next phase should be developed with the industry rather than in isolation from it.

What's next: - Sequrin is now looking for a design partner to help test and refine the platform before any production deployment. - The company expects the next phase to focus on controlled development and evaluation with industry input. - Sequrin will move toward live-data use only if the necessary governance, privacy, security and organisational approvals are in place. - The company plans to measure success by investigative utility rather than model performance alone.

The bottom line: - Sequrin is betting that claims-integrity software for healthcare works best when it helps investigators think better, not when it tries to make the final fraud call itself.